Bora Pharmaceuticals Co., Ltd. (TPE:6472)
Taiwan · Delayed Price · Currency is TWD 455.00
-6.00 (-1.30%)
At close: Mar 26, 2026
Bora Pharmaceuticals Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 2,981 | 3,853 | 3,030 | 1,392 | 749.74 |
Depreciation & Amortization | 1,024 | 968.8 | 563.53 | 285.23 | 185.31 |
Other Amortization | 62.08 | 57.53 | 42.76 | 39.95 | 24.85 |
Loss (Gain) From Sale of Assets | -43.54 | 27.99 | 5 | 3.38 | 2.22 |
Asset Writedown & Restructuring Costs | 151.42 | - | - | - | - |
Loss (Gain) From Sale of Investments | -2,965 | -11.56 | 1,044 | 47.79 | -0.78 |
Loss (Gain) on Equity Investments | 452.96 | 0.04 | - | - | - |
Stock-Based Compensation | 78.62 | 135.98 | 102.81 | 31.83 | 15.77 |
Other Operating Activities | 2,317 | -833.44 | 317.17 | 205.67 | 309.69 |
Change in Accounts Receivable | 1,149 | -1,372 | 2,157 | -1,509 | -282.39 |
Change in Inventory | 2,051 | -341.82 | -124.5 | 99.39 | 172.37 |
Change in Accounts Payable | 140.29 | -663.52 | -90.88 | 107.17 | 9.81 |
Change in Unearned Revenue | 131.6 | 19.31 | 134.72 | -11.77 | 16.36 |
Change in Other Net Operating Assets | -1,285 | -505.36 | -2,569 | 1,318 | 33.68 |
Operating Cash Flow | 4,504 | 980.02 | 4,614 | 2,010 | 1,237 |
Operating Cash Flow Growth | 359.54% | -78.76% | 129.53% | 62.54% | 595.56% |
Capital Expenditures | -928.67 | -528.1 | -297.71 | -194.81 | -163.48 |
Sale of Property, Plant & Equipment | 6.11 | 12.59 | 3.37 | 37.95 | 0.08 |
Cash Acquisitions | -620.21 | -10,265 | -999.99 | -4,514 | -3.83 |
Divestitures | -1,004 | - | - | 24 | - |
Sale (Purchase) of Intangibles | -43.98 | -158.95 | -1,132 | -5.41 | -200.1 |
Investment in Securities | -1,092 | 422.21 | -41.7 | 323.98 | - |
Other Investing Activities | 303.68 | -162.44 | 10.92 | 47.49 | 141.48 |
Investing Cash Flow | -3,380 | -10,680 | -2,458 | -4,281 | -225.85 |
Short-Term Debt Issued | 1,370 | 1,824 | - | 772.33 | - |
Long-Term Debt Issued | 460 | 15,021 | 4,804 | 5,554 | 100 |
Total Debt Issued | 1,830 | 16,844 | 4,804 | 6,327 | 100 |
Short-Term Debt Repaid | - | - | -1,398 | - | -572.17 |
Long-Term Debt Repaid | -1,410 | -2,910 | -5,176 | -1,916 | -172.03 |
Total Debt Repaid | -1,410 | -2,910 | -6,574 | -1,916 | -744.2 |
Net Debt Issued (Repaid) | 419.37 | 13,934 | -1,769 | 4,411 | -644.2 |
Issuance of Common Stock | 127.55 | 94.89 | 33.94 | 3.9 | 66.91 |
Repurchase of Common Stock | -139.26 | -389.13 | - | -53.09 | - |
Common Dividends Paid | -1,449 | -1,233 | -619.13 | -238.8 | -109.77 |
Other Financing Activities | -335.65 | -336.63 | -85.72 | 471.9 | -54.34 |
Financing Cash Flow | -1,377 | 12,071 | -2,440 | 4,595 | -741.4 |
Foreign Exchange Rate Adjustments | -499.34 | 404.86 | 56.13 | 46.89 | -28.63 |
Net Cash Flow | -752.31 | 2,776 | -228.03 | 2,371 | 240.76 |
Free Cash Flow | 3,575 | 451.92 | 4,316 | 1,815 | 1,073 |
Free Cash Flow Growth | 691.04% | -89.53% | 137.76% | 69.15% | 3657.55% |
Free Cash Flow Margin | 18.80% | 2.59% | 30.39% | 17.30% | 21.90% |
Free Cash Flow Per Share | 18.95 | 3.20 | 34.74 | 15.33 | 9.19 |
Cash Interest Paid | 266.74 | 382.69 | 156.01 | 105.04 | 54.12 |
Cash Income Tax Paid | 474.88 | 1,057 | 896.47 | 367.75 | 18.16 |
Levered Free Cash Flow | 2,901 | -4,579 | 3,148 | 1,037 | 625.48 |
Unlevered Free Cash Flow | 3,204 | -4,279 | 3,255 | 1,105 | 658.99 |
Change in Working Capital | 2,188 | -2,863 | -491.94 | 4.31 | -50.16 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.